Navigation Links
CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting

BRANFORD, Conn., April 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation announced today that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007. A total of five poster presentations on belinostat (PXD101) and one poster presentation on velafermin will be made during the conference.

    Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:


    -- "Activity of PXD101, an HDAC inhibitor, used alone or in combination

        with 5-FU in preclinical gastroesophageal studies," (Abstract #691)

        during the conference's HDAC Inhibitors I poster session on Sunday,

        April 15th in the Exhibit Hall, Poster Section 28 on Poster Board #14


    -- "Gene expression screen in cell panel selected for varying sensitivity

        towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals

        potential predictors of HDACi sensitivity," (Abstract #687) during the

        conference's HDAC Inhibitors I poster session on Sunday, April 15th in

        the Exhibit Hall, Poster Section 28 on Poster Board #10


    -- "The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell

        growth and expression of viral and host genes in hepatitis B virus

        (HBV)-carrying hepatocellular carcinoma (HCC) cell lines," (Abstract

        #696) during the conference's HDAC Inhibitors I poster session on

        Sunday, April 15th in the Exhibit Hall, Poster Section 28 on Poster

        Board #19


    -- "The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder

        cancer cell growth both in-vitro and in-vivo," (Abstract #2211) during

        the conference's Mouse Models of Cancer 2: Therapeutic A
pproaches

        poster session on Monday, April 16th in the Exhibit Hall, Poster

        Section 23 on Poster Board #9


    -- "The HDAC inhibitors romidepsin and PXD101 interact synergistically

        with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in

        association with NF-.B inactivation," (Abstract #1835) during the

        conference's Targeted Agents and Other Novel Therapies poster session

        on Monday, April 16th in the Exhibit Hall, Poster Section 7 on Poster

        Board #21


    Velafermin, protein for the prevention of severe oral mucositis:


    -- "Velafermin (rhFGF-20) reduces fractionated radiation- induced oral

        mucositis in hamsters," (Abstract #3758) during the conference's

        Cytosolic Signaling 2 poster session on Tuesday, April 17th in the

        Exhibit Hall, Poster Section 16 on Poster Board #15.


    About CuraGen

CuraGen Corporation is a biopharmaceutical company developing diverse approaches, including novel protein, antibody, antibody- drug conjugate and small molecule therapeutics. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of patients with cancer and inflammatory diseases. CuraGen is focused on bringing velafermin, belinostat and CR011-vcMMAE through clinical development, and maintains a portfolio of earlier-stage compounds that have the potential to treat cancer and inflammatory diseases. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit www.curagen.com.

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospect may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements cont ained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    CRGN-P


    Contact:

    Glenn Schulman, Pharm.D.

    Director of Investor Relations

    

    (888) 436-6642

gschulman@curagen.com

CONTACT: Glenn Schulman, Pharm.D., Director of Investor Relations ofCuraGen Corporation, +1-888-436-6642 or gschulman@curagen.com

Web site: http://www.curagen.com/

Ticker Symbol: (NASDAQ-NMS:CRGN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
(Date:4/29/2016)... , ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon ... is a very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to ... is a procedure that involves one or both jaw bones. This surgery is performed to ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
(Date:4/29/2016)... ... 29, 2016 , ... Innovations with Ed Begley Jr., announced ... airing third quarter 2016 via Discovery Channel. Dates and show times TBA. , ... located in Greenwood, Wisconsin applies product research and development and continuous technological improvements ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
Breaking Medicine News(10 mins):